<DOC>
	<DOCNO>NCT02611063</DOCNO>
	<brief_summary>The purpose study evaluate whether fostamatinib , drug block activate B cell effective prevent chronic graft v host disease ( cGVHD ) allogeneic stem cell transplant . Activated B cell may play role development cGVHD . Inhibiting B cell activation use fostamatinib allogeneic stem cell transplant may prevent development cGVHD .</brief_summary>
	<brief_title>Evaluation Fostamatinib Patients With cGVHD After Allogeneic Stem Cell Transplant</brief_title>
	<detailed_description>Design &amp; Procedures All patient undergo allogeneic stem cell transplantation ( HCT ) accord program 's standard . No specific condition regimen mandate . The stem cell source must peripheral blood stem cell . Prophylaxis acute GVHD must standard agent ( sirolimus and/or tacrolimus and/or methotrexate and/or cyclosporine ) . Participation trial evaluate novel agent therapy acute GVHD allow , long experimental agent discontinue &gt; 14 day prior trial entry . Therapy : Patients receive 100mg daily , 150mg daily 100 mg bid begin 90 day allogeneic transplantation continue 1 year day transplant . Dosage determine use modify continual reassessment method . Patient evaluation : Patients evaluate cGVHD toxicity minimum day 1 ( baseline ) , day 3 , day 11 , day 25 , day 39 , day 60 , day 88 , day 116 , day 144 , day 186 , day 228 , day 275 initiation protocol therapy . While assessment safety determine base evaluation day 60 , patient may stay therapy 1 year transplantation ( study treatment day 275 ) . In addition , patient observe one year stop study treatment evaluation toxicity cGVHD clinic visit 6 12 month completion study therapy . If time within first year transplantation , study subject determine evidence moderate severe stage cGVHD accord NIH consensus criterion global severity , subject remove clinical trial appropriate therapy cGVHD administer per treat physician 's discretion . The study subject may continue receive Fostamatinib per guideline clinical trial event mild stage cGVHD diagnose . If cGVHD develops observation period , second course Fostamatinib 100 % tolerate study dose may give observation period . Immunosuppressive medication taper accord treat physician ' discretion careful attention clinical trial treatment plan participate subject already enrol . Laboratory sample obtain accord study schedule . The following test collect analyzed study : complete blood count , serum chemistry , liver function test ( LFTs ) , chimerism analysis indicate , immunology/correlative science study . This study open member demographic group meet eligibility criterion . Approximately 18 subject recruit Duke . A total eighteen patient receive fostamatinib begin day 90 allogeneic transplantation . The safety assessment determine day 60 . Three dose level consider : 100 mg qd , 150 mg qd , 100 mg bid , target dose-limiting toxicity ( DLT ) probability 0.33 . The Bayesian model average continual reassessment method ( BMA-CRM ) use trial . [ 15 ] The investigator study target molecular mechanism underpin aberrant B-cell signaling cGVHD . Corollary study determine whether B T cell subset and/or soluble B-cell activation factor alter Syk inhibition . The objective implement preemptive target therapy decrease excessive immune activation patient .</detailed_description>
	<criteria>1 . Patients undergone allogeneic stem cell transplantation treatment hematological malignancy eligible . Transplant must occur 90 day start study drug . 2 . Peripheral blood stem cell must use stem cell source . 3 . Patients must receive transplantation adult donor ( relate unrelated ) Human Leukocyte Antigen ( HLA ) match mismatched 1 locus ( 5/6 ) mismatch one allele ( 3/6 ) . Class I II type perform standard method institution . 4 . Complete remission hematological malignancy prior transplantation . All patient must undergo appropriate staging malignancy prior transplantation include bone marrow aspirate/biopsy radiographic scanning indicate . 5 . Patients undergone nonmyeloablative stem cell transplant must &gt; 65 % donor lymphoid hematopoiesis within 30 day study enrollment . 6 . Patient age great 18 year age . 7 . ECOG performance status 02 Karnofsky Performance Status ( KPS ) &gt; 60 . 8 . Must able tolerate routine oral posaconazole voriconazole fungal prophylaxis therapy . 9 . Written informed consent . 1 . Recipients allogeneic stem cell transplantation use single multiple umbilical cord blood unit use bone marrow . 2 . Participation clinical trial evaluate another preventative strategy chronic GVHD ongoing participation clinical trial therapy acute GVHD . Prior completion experimental therapy acute GVHD permissible experimental agent use &gt; 14 day prior enrollment . 3 . Evidence relapse hematologic malignancy base routine restaging study . 4 . Evidence active uncontrolled infection ( bacterial , viral fungal ) evidence natural exposure Hepatitis B , Hepatitis C HIV without demonstration PCR negativity say virus . Vaccination Hepatitis B exclusion criterion . 5 . Any evidence ongoing gastrointestinal hepatic acute GVHD evidence great ongoing Stage I cutaneous acute GVHD time enrollment . Ongoing , taper therapy resolve acute GVHD permissible . 6 . Patients GVHD chronic feature diagnose prior day +60 prior enrollment ineligible . 7 . Patients may receive one Donor Lymphocyte Infusion ( DLI ) , DLI must administer &gt; 6 week prior enrollment study , plan DLI upcoming 30 day . 8 . Any major cardiovascular even within 6 month study initiation , include limited myocardial infarction , unstable angina , cerebrovascular accident , pulmonary embolism , heart failure uncontrolled medication New York Heart Association Class III IV heart failure . 9 . Uncontrolled poorly control hypertension , define systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mmHg , whether subject receive antihypertensive treatment . Subjects may rescreened blood pressure successfully promptly control within 5 day use conventional antihypertensive therapy achieve optimal blood pressure control ( &lt; 140/90 mmHg ) . 10 . Active hemolytic anemia . 11 . History arterial venous thrombosis ( unless single episode venous thrombosis &gt; 1 year prior study initiation ) . 12 . Liver function test abnormality include ALT AST &gt; 3.0x ULN ; total bilirubin &gt; 1.5x ULN ; alkaline phosphatase &gt; 2.5 x ULN 13 . Neutrophil count &lt; 1.5 x 10e9/L platelet count &lt; 75 x10e9/L 14 . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>allogeneic stem cell transplant</keyword>
</DOC>